Showing Results for
- Academic Journals (13)
Search Results
- 13
Academic Journals
- 13
- 1From:Oncology (Vol. 36, Issue 2) Peer-ReviewedLYMPHOMA Parsaclisib Provides Rapid and Durable Responses in Marginal Zone Lymphoma In the phase 2 CITADEL-204 trial (NCT03144674), patients with relapsed or refractory marginal zone lymphoma (MZL) who were treated...
- 2From:Oncology (Vol. 36, Issue 2) Peer-ReviewedThe 2021 American Society of Hematology Annual Meeting & Exposition (ASH 2021) took place in December in Atlanta, Georgia, and included an in-person event as well as a virtual platform. Presenters and attendees from the...
- 3From:Oncology (Vol. 36, Issue 2) Peer-ReviewedThe accompanying article is an excellent overview of a field perceived to be evolving quickly, but how quick is that evolution in reality? Perspective of Experienced Clinician (BKL) Providing peer review and...
- 4From:Oncology (Vol. 36, Issue 2) Peer-ReviewedEstablished physicians often mentor younger physicians within the same field. Recently, formal mentoring has increased, with systemized processes becoming more and more prevalent. When considering a mentorship,...
- 5From:Oncology (Vol. 36, Issue 2) Peer-ReviewedConflicts of interest ultimately focus on roles, responsibility, and integrity. Drug development, especially in oncology, is a complicated process that involves many individuals and entities. Each makes a specific...
- 6From:Oncology (Vol. 36, Issue 2) Peer-ReviewedFollicular lymphoma (FL) is the most common indolent lymphoma and is characterized by a relapsing and remitting course. In addition to significant biologic heterogeneity, the clinical trajectory for patients is variable,...
- 7From:Oncology (Vol. 36, Issue 2) Peer-ReviewedNeoadjuvant systemic therapy is a preferred treatment approach for a number of tumor types due to many potential advantages over upfront surgery, including tumor downstaging, early treatment of micrometastatic disease,...
- 8From:Oncology (Vol. 36, Issue 2) Peer-ReviewedINTRODUCTION: Financial conflicts of interest (COIs) represent a common and complex issue in hematology and oncology. However, little is known about the timing of when COIs begin to develop during a career trajectory. We...
- 9From:Oncology (Vol. 36, Issue 2) Peer-ReviewedAn estimated 70% of patients with colorectal cancer will develop liver metastases during the course of their disease. While the first-line treatment for hepatic metastases is resection, most patients with colorectal...
- 10From:Oncology (Vol. 36, Issue 2) Peer-ReviewedFACULTY, STAFF, AND PLANNERS' DISCLOSURES In accordance with ACCME Guidelines, PER[R] has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep...
- 11From:Oncology (Vol. 36, Issue 2) Peer-ReviewedIn this issue of ONCOLOGY[R], contributors focus on elements of an oncologist's early career that correlate with overall success. In original research first presented at the 2021 American Society of Clinical Oncology...
- 12From:Oncology (Vol. 36, Issue 2) Peer-ReviewedONCOLOGY[R]: Describe the mechanism of action of mobocertinib? MAY: Mobocertinib is a small molecule oral EGFR tyrosine kinase inhibitor [TKI], and it was designed specifically to target EGFR exon 20 insertion...
- 13From:Oncology (Vol. 36, Issue 2) Peer-ReviewedMEET OUR EXPERT Michael Choti, MD, MBA, FACS is a surgical oncologist of the hepatobiliary tract and the pancreas; division chief of surgery at Banner MD Anderson Cancer Center at Banner Gateway Medical Center in...